WENTWORTH KORY JAMES 4

What Happened
Kory J. Wentworth, Chief Financial Officer of Entrada Therapeutics, reported a sale of 2,500 shares on April 1, 2026. The shares were sold at $12.95 each for a total transaction value of $32,375. This was a sale (code S), not a purchase—sales are often routine liquidity events rather than a direct bullish signal.

Key Details

• Transaction date and price: 2026-04-01, 2,500 shares at $12.95 per share (total $32,375).
• Transaction type: Reported as an open-market or private sale (SEC code S).
• Shares owned after transaction: Not specified in the details provided.
• Footnote: Transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 6, 2025.
• Filing timeliness: Report filed 2026-04-02 for a 2026-04-01 transaction (filed next business day; not indicated as late).

Context
A 10b5-1 plan is a pre-arranged trading program that allows insiders to sell shares at predetermined times, which reduces the likelihood the sale reflects current, undisclosed company information. For retail investors, purchases generally carry more signal value than routine sales under 10b5-1 plans. This report is factual and does not imply insider opinion about Entrada’s near-term prospects.